Last update 20 Mar 2025

DYNE-101

Overview

Basic Info

Drug Type
Antibody oligonucleotide conjugates
Synonyms
Target
Action
modulators
Mechanism
DMPK modulators(DM1 protein kinase modulators), RNA interference
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (European Union), Fast Track (United States)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myotonic DystrophyPhase 2
New Zealand
05 Sep 2022
Myotonic DystrophyPhase 2
United Kingdom
05 Sep 2022
Myotonic DystrophyPhase 2
Germany
05 Sep 2022
Myotonic DystrophyPhase 2
France
05 Sep 2022
Myotonic DystrophyPhase 2
Netherlands
05 Sep 2022
Myotonic DystrophyPhase 2
Italy
05 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
56
DYNE-101 1.8 mg/kg Q4W
(szjkclqrcf) = 4 (7%) tmfxbaswps (vukntlvwgz )
Positive
20 May 2024
DYNE-101 3.4 mg/kg Q4W
Phase 1/2
32
DYNE-101 1.8 mg/kg Q4W
(ralktpeehx) = svllzpkjjv celntlhgyr (afzmcfdrgn )
Positive
03 Jan 2024
DYNE-251 3.4 mg/kg Q4W
(ralktpeehx) = bnhwagskht celntlhgyr (afzmcfdrgn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free